Racemic ibuprofen inhibited collagen-stimulated thromboxane B2 formation in human platelets, with IC50 values of 50 ± 27 μM in platelet-rich plasma and 0.3 ± 0.1 μM in washed platelets (mean ± s.e. mean; 3–6 experiments per group). The matrix dependence limits transfer of these values to other assays. S(+)-ibuprofen was more potent than the racemate, while R(−)-ibuprofen was less potent. [2]
Ibuprofen binding geometry in murine COX-2
Biochemical assay · Purified wild-type murine COX-2; X-ray crystal structure [1]
The structure places the ibuprofen carboxylate in a salt bridge with Arg-120 and a hydrogen bond with Tyr-355 at the cyclooxygenase-channel entrance. The reported refined model contains S-ibuprofen in both monomers; this record does not infer a quantitative enantiomer affinity ratio.
Literature-Reported Treatment Conditions
- Treatment concentration
- Five-fold molar excess of racemic (R/S)-ibuprofen relative to reconstituted enzyme
- Exposure duration
- 30 min on ice before crystallization
- Method
- X-ray crystallography
- Reported limits
- Supplier, lot and enantiomeric assay of ibuprofen are not specified in the acquired main manuscript; Supplementary Figures 1–3 and tables were not retrieved.
Methods and source locations
Compound reported in the paper: Ibuprofen; Compound label in the paper: Racemic (R/S)-ibuprofen used for crystallization
Binding geometry in this murine protein crystal; no human potency or therapeutic dose extrapolation.
Sections 2.1–2.2 and 3.1; Figure 1 and caption; section 4 final paragraph
Wild-type and mutant COX-2 inhibition by racemic ibuprofen
Biochemical assay · Purified wild-type, R120A and Y355F murine COX-2; arachidonic-acid oxygenation [1]
At 100 μM racemic ibuprofen, wild-type enzyme activity decreased by 40% as reported in the Results. R120A and Y355F were not inhibited under the same assay conditions. Each construct was compared with its own no-ibuprofen control.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 μM (R/S)-ibuprofen during preincubation and in the assay; 100 μM arachidonic acid substrate
- Exposure duration
- 30 min on ice before assay; residual activity assayed at 37°C
- Method
- Clark-type oxygen electrode; 5 μg enzyme in 3 mL containing 100 mM Tris pH 8, 1 mM phenol and 5 μM Fe3+-PPIX
- Reported limits
- Ibuprofen stock solvent and supplier are not specified in the acquired main manuscript; precise reaction readout duration and error-bar definition are not supplied in Figure 2 caption.
Methods and source locations
Compound reported in the paper: Ibuprofen; Compound label in the paper: Racemic (R/S)-ibuprofen
A single-concentration murine enzyme comparison; 100 μM is an assay concentration, not an IC50 or an animal dose.
Section 2.3; section 3.2 first paragraph; Figure 2 and caption
Wild-type COX-2 arachidonic-acid oxygenation relative to no-ibuprofen control: Oxygen-electrode assay; reactions repeated in triplicate (replication type not further specified). — Section 3.2 first paragraph; Figure 2 and caption
R120A and Y355F COX-2 arachidonic-acid oxygenation: Same assay and concentration as wild type; no exact mutant bar heights inferred. — Section 3.2 first paragraph; Figure 2 and caption
Matrix-dependent inhibition of human platelet responses
Cell-based study · Human platelet-rich plasma and washed platelets; collagen-stimulated aggregation and thromboxane B2 formation [2]
Racemic ibuprofen inhibited collagen-induced aggregation and thromboxane B2 formation. Its IC50 values were much lower in washed platelets than in platelet-rich plasma. The S(+)-enantiomer was more potent and R(−)-ibuprofen less potent in both matrices. These are cellular endpoints, not purified-enzyme binding constants.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response experiments; collagen 2.5 μg/mL for the adopted Tables 1–2
- Exposure duration
- Ibuprofen added at beginning of an 8-min preincubation; thromboxane sampling described at 8 min in the aggregation assay
- Method
- Photometric aggregation at 37°C; supernatant thromboxane B2 measured by radioimmunoassay
- Vehicle
- Ibuprofen dissolved in 50 mM Tris buffer, pH 7.4; final solvent concentrations reported not to affect the assay
- Reported limits
- Individual concentration-series points are graphical rather than tabulated. Tables report 3–6 experiments per group, without a per-endpoint donor count or explicit biological/technical replication allocation.
Methods and source locations
Compound reported in the paper: Ibuprofen; Compound label in the paper: Racemic ibuprofen; S(+)- and R(−)-ibuprofen comparators
In vitro human platelet response; matrix-specific IC50 values must not be used as a universal COX potency or dosing recommendation.
Pages 236–238: platelet and washed-platelet methods, reagents, statistics, platelet results; page 237 Tables 1–2 and Figure 1
Collagen-stimulated thromboxane B2 formation in platelet-rich plasma: Mean ± s.e. mean of 3–6 experiments in each group, as stated in table footnotes; no-ibuprofen stimulated control response; photometric aggregation or thromboxane B2 radioimmunoassay. — Page 237, Table 1 (rac-ibuprofen row); platelet methods pages 236–237; Figure 1 for thromboxane concentration-response
Collagen-stimulated thromboxane B2 formation in washed platelets: Mean ± s.e. mean of 3–6 experiments in each group, as stated in table footnotes; no-ibuprofen stimulated control response; photometric aggregation or thromboxane B2 radioimmunoassay. — Page 237, Table 2 (rac-ibuprofen row); platelet methods pages 236–237; Figure 1 for thromboxane concentration-response
Collagen-stimulated aggregation in platelet-rich plasma: Mean ± s.e. mean of 3–6 experiments in each group, as stated in table footnotes; no-ibuprofen stimulated control response; photometric aggregation or thromboxane B2 radioimmunoassay. — Page 237, Table 1 (rac-ibuprofen row); platelet methods pages 236–237; Figure 1 for thromboxane concentration-response
Collagen-stimulated aggregation in washed platelets: Mean ± s.e. mean of 3–6 experiments in each group, as stated in table footnotes; no-ibuprofen stimulated control response; photometric aggregation or thromboxane B2 radioimmunoassay. — Page 237, Table 2 (rac-ibuprofen row); platelet methods pages 236–237; Figure 1 for thromboxane concentration-response